Nyvigan

Vulvovaginal candidiasis is an infection of the estrogenised vagina and vestibulum which can also extend to the outer sides of the labia minora, the labia majora, the intercrural-region and the perianal region.

75% of women are affected at least once during their lifetime es. 90% of those affected are considered uncomplicated and Candida (fungus) is the cause.

Resistance to Candida treatment is a major and growing problem, a sharp increase has been seen in recent decades.

Nyvigan (nystatin) is a combination treatment (pessaries + cream) for the treatment of vulvovaginal Candida.

In vitro and in vivo studies show that nystatin has a good effect and there has been no development of resistance in Candida strains.

In addition Nyvigan offers:

  • No systemic exposure
  • No known drug interactions
  • Can be used during any stage of pregnancy and breast-feeding

Nyvigan (nystatin), Ointment 100 000 IU/g + vaginal tablets 100 000 IU, Rx, EF.

ATC code: G01AA01

Therapeutic indications: Nyvigan is indicated for the treatment of vulvovaginal candidiasis in adults. Please ensure compliance with official guidelines on correct use of antimycotics.

Dosing (ointment): twice daily to the infected skin areas on the outer areas of the genitals.

Dosing (vaginal tablets): one or two vaginal tablets once daily.

Storage: do not store above 25°C. Vaginal tablets should be stored in the original package, in order to protect from light.

Package information: combination pack with 25 g ointment (tube) + 6 vaginal tablets (blisters).

For full information regarding prescription and SPC (November 2020) please see www.fass.se

Please note that the information you will find in this section is for healthcare professionals

Please confirm that you are a healthcare professional